Efficacy and Safety of Risankizumab in Psoriatic Patients With a History of Malignancy: Real‐World Evidence From a Multicentre Spanish Study

The management of psoriasis in patients with a history of malignancy is challenging. We conducted a multicentre, retrospective study in 17 Spanish centres including 69 patients with moderate-to-severe psoriasis and a previous or current malignancy treated with risankizumab; 94.2% of patients showed no recurrence or progression of cancer, while 5.8% experienced progression during therapy. Risankizumab was associated with substantial improvement in psoriasis, with a mean final PASI score of 0.9 ± 1.7 after a mean exposure time of 72 weeks. Tolerance was favourable, and no tumour recurrence was considered treatment-related. These findings support risankizumab as an effective and safe therapeutic option for this subpopulation.

Authors

Institutions

Publication Details

Journal
Australasian Journal of Dermatology
Published
2025-12-05
DOI
https://doi.org/10.1111/ajd.70012
Primary Topic
Psoriasis: Treatment and Pathogenesis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and Safety of Risankizumab in Psoriatic Patients With a History of Malignancy: Real‐World Evidence From a Multicentre Spanish Study

Laura García Fernández, I. Belinchón, Ricardo Ruíz‐Villaverde, Sergio Santos‐Alarcón et al.
Australasian Journal of Dermatology
Psoriasis: Treatment and Pathogenesis
article

Efficacy and Safety of Risankizumab in Psoriatic Patients With a History of Malignancy: Real‐World Evidence From a Multicentre Spanish Study

Laura García Fernández, I. Belinchón, Ricardo Ruíz‐Villaverde, Sergio Santos‐Alarcón, Fernando Toledo Alberola, Adrián Ballano Ruiz, E. Vilarrasa Rull, María Castellanos‐González, Francisco Javier Melgosa Ramos, Marta Ferrán Farrés, Ofelia Baniandrés, Jorge Magdaleno‐Tapial, Luca Schneller‐Pavelescu, Javier Mataix Díaz, María Asunción Ballester Martínez, Almudena Mateu Puchades, Susana Medina Montalvo
article en

Abstract

The management of psoriasis in patients with a history of malignancy is challenging. We conducted a multicentre, retrospective study in 17 Spanish centres including 69 patients with moderate-to-severe psoriasis and a previous or current malignancy treated with risankizumab; 94.2% of patients showed no recurrence or progression of cancer, while 5.8% experienced progression during therapy. Risankizumab was associated with substantial improvement in psoriasis, with a mean final PASI score of 0.9 ± 1.7 after a mean exposure time of 72 weeks. Tolerance was favourable, and no tumour recurrence was considered treatment-related. These findings support risankizumab as an effective and safe therapeutic option for this subpopulation.

Australasian Journal of DermatologyVol. 67(1)
Hospital de Sant Pau (ES), Hospital General Universitario Gregorio Marañón (ES), Hospital Universitari Sant Joan D'Alacant (ES), Hospital Universitario Príncipe de Asturias (ES), Instituto de Investigación Biosanitaria de Granada (ES), Hospital General Universitario de Elche (ES), Hospital Universitario Doctor Peset (ES), Hospital Universitario del Sureste (ES), Hospital General Universitario De Valencia (ES), Hospital Del Mar (ES), Hospital General Universitario de Alicante Doctor Balmis (ES), Hospital Vega Baja (ES), Hospital Universitario Lluís Alcanyís (ES), Hospital Universitario del Henares (ES), Hospital Marina Baixa (ES), Hospital Virgen de los Lirios (ES), Hospital Universitario Ramón y Cajal (ES)
Openalex Percentile: Top 56%
Psoriasis: Treatment and Pathogenesis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.